Advertisement

U.S. markets open in 3 hours 7 minutes

S&P Futures
4,338.50
-3.00(-0.07%)
Dow Futures
34,012.00
-43.00(-0.13%)
Nasdaq Futures
14,160.00
+1.50(+0.01%)
Russell 2000 Futures
1,964.90
-7.80(-0.40%)
Crude Oil
87.36
+0.01(+0.01%)
Gold
1,810.60
-19.10(-1.04%)

Advertisement

COMING UP

Q4 GDP preview: Economists look for growth acceleration before Omicron impact

Check back at 8:30 a.m. ET for the results

Rocket Pharmaceuticals, Inc. (RCKT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

15.94

-0.45

(-2.75%)

At close: 04:00PM EST

16.03

+0.09

(+0.59%)

After hours:

04:01PM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Engulfing Line (Bullish)

View all chart patterns

Performance Outlook

Previous Close	16.39
Open	16.99
Bid	0.00 x 800
Ask	0.00 x 900
Day's Range	15.80 - 17.43
52 Week Range	14.95 - 67.48
Volume	514,245
Avg. Volume	520,936

Market Cap	1.027B
Beta (5Y Monthly)	1.47
PE Ratio (TTM)	N/A
EPS (TTM)	-3.04
Earnings Date	Feb 23, 2022 - Feb 28, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	65.33

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RCKT

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Rocket Pharmaceuticals, Inc.
RGNX: Lowering target price to $28.00REGENXBIO INC has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
Rating
Fair Value
Economic Moat
8 days agoArgus Research

All

News

Press Releases

Research Reports

Business Wire
Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs
CRANBURY, N.J., January 11, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today shares expected milestones for 2022, which were discussed yesterday during the Company’s virtual presentation at the 40th Annual J.P. Morgan Healthcare Conference.
Business Wire
Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J., January 04, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10 at 1:30 p.m. ET.
Insider Monkey
10 Healthcare Stocks to Buy According to Lee Ainslie’s Maverick Capital
In this piece, we will take a look at the ten healthcare stocks to buy according to Lee Ainslie’s Maverick Capital. If you want to jump ahead to the top five stocks in this list and skip the details about Mr. Ainslie and his investment firm then head on over to 5 Healthcare Stocks to […]